Cedric Nasnas

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML”.

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies

Nature Communications(2024)10.1038/s41467-024-45916-6

N/A

0.631DataRank · unranked

66 citations

Patrick K. Reville, Mhd Yousuf Yassouf, Fatima Zahra Jelloul, Christopher Ly, Poonam N. Desai +27 more

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3

N/A

0.561DataRank · unranked

17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more